undamentalytics Newsletter

Thompson Peter A.: insider trades

Director at 4 companies we cover. 15 open-market purchases and 7 sales not made under a pre-set plan, reported from May 20, 2016 to July 1, 2025.

Would copying Thompson Peter A.’s purchases have beaten the S&P 500?

Too few purchases to judge. Only 13 purchases have 12 months of prices after the report; we judge insiders once they have 20. The figures below can swing a long way on a handful of trades. Buying each purchase the day after it was reported, an equal amount each, and holding it 12 months or until they reported a sale would have turned $10,000 on May 23, 2016 into $9,847 by November 2, 2026, −0.1% a year. The copy held shares only 65% of the time, so the fair comparison is the S&P 500 on those same days with Treasury bills otherwise: $29,916, +11.1% a year (the S&P 500 held throughout made $43,610, +15.2% a year). Beta against the index was 0.82. Twelve months after each report, the average purchase was −7.6% against the S&P 500 (median −31.6%), and 31% beat it. Measured from the trade date, the insider’s own timing, the average was −5.1%. After their sales, the shares moved −30.5% against the index over 12 months on average (a negative figure means selling was the right call); 100% trailed it.

With 296 insiders tested, some will look skilled or unskilled by chance alone: when we replaced each insider’s stocks with random companies bought on the same days, about 5.7 cleared the bar ahead and 23.3 behind. One record on its own proves little.

$0$20.0k$40.0k 201620182020202220242026 $43.6k$29.9k$9.8k
Copying Thompson Peter A.S&P 500, same days investedS&P 500, held throughout $10,000 copying Thompson Peter A.’s open-market purchases from May 23, 2016, before costs and taxes, marked weekly. Each purchase gets the same starting stake, bought at the close of the first trading day after the report and sold 12 months later or the day after a reported sale of that stock; uninvested money earns the Treasury bill rate. “Same days invested” holds the S&P 500 only on the days the copy held shares, Treasury bills otherwise.
Return a year, copying
−0.1%
S&P 500, same days invested
+11.1% (held throughout +15.2%)
Time in shares
65%
Sharpe ratio (S&P 500)
0.30 (0.75)
Biggest drop (S&P 500)
−95% (−34%)
Market sensitivity (beta)
0.82
Purchases copied
13

Trade by trade

Thompson Peter A.: trades against the S&P 500 afterwards
MeasuredTrades countedAverage vs S&P 500MedianWent the right wayYearst-statisticp-valueEvidence
Purchases, 3 months after the report 13 +1.9% −5.0% 46% 7 −0.51 0.63 No reliable evidence
Purchases, 6 months after the report 13 +3.4% −1.3% 39% 7 0.31 0.77 No reliable evidence
Purchases, 12 months after the report 13 −7.6% −31.6% 31% 7 0.41 0.69 No reliable evidence
Purchases, 12 months after the trade 12 −5.1% −29.9% 33% 6 0.73 0.50 No reliable evidence
Sales, 3 months after the report 6 −21.8% −17.9% 83% 2 — — Not enough years
Sales, 12 months after the report 6 −30.5% −23.1% 100% 2 — — Not enough years
Sales, 12 months after the trade 6 −27.6% −19.3% 100% 2 — — Not enough years

“Average vs S&P 500” is the stock’s return including dividends minus the index’s over the same dates, from the close on the first trading day after the report, or from the close on the trade date. Only windows that have finished are counted. For sales, a negative figure means the stock lagged after it was sold, so selling was the right call (green). “Went the right way” is the share of purchases that beat the index, or of sales that trailed it. The t-statistic uses one average per year of reports, because one person’s trades bunch into the same stock and weeks, and needs trades in at least four different years; the p-value comes from the t distribution with that number of years (with four years, a t of 2 has p = 0.14). “Some evidence” means p under 5%, “strong evidence” p under 1% over at least six years.

Companies traded

CompanyTitle on the latest filingPurchasesSalesFirst reportLatest report
Corvus Pharmaceuticals, Inc. CRVS —102May 20, 2016July 1, 2025
Edgewise Therapeutics, Inc. EWTX —40May 20, 2022April 4, 2025
Janux Therapeutics, Inc. JANX —03December 17, 2021December 30, 2021
ARS Pharmaceuticals, Inc. SPRY —12August 31, 2023August 28, 2024

Trades and what followed

Moves are against the S&P 500; green means the trade went the insider’s way.

ReportedTradedCompanyTradeValue3 months after report12 months after report12 months after trade
July 1, 2025June 27, 2025 CRVS Sale $4,893,541 not yetnot yetnot yet
April 4, 2025April 3, 2025 EWTX Purchase $10,000,000 −5.0%+147.0%+115.1%
August 28, 2024August 26, 2024 SPRY Sale $1,088,035 +4.4%−32.9%−19.7%
August 23, 2024August 21, 2024 SPRY Sale $11,497,963 −0.5%−19.7%−15.2%
January 25, 2024January 23, 2024 EWTX Purchase $4,999,995 −6.7%+47.0%+56.1%
August 31, 2023August 29, 2023 SPRY Purchase $3,100,000 −32.5%+44.0%+57.0%
September 16, 2022September 16, 2022 EWTX Purchase $4,999,999 −10.1%−45.2%−52.2%
May 20, 2022May 18, 2022 EWTX Purchase $994,980 +44.2%+33.3%+17.7%
December 30, 2021December 29, 2021 JANX Sale $820,120 −18.8%−10.4%−13.5%
December 23, 2021December 21, 2021 JANX Sale $2,268,600 −30.5%−23.3%−21.5%
December 17, 2021December 16, 2021 JANX Sale $7,500,231 −17.1%−22.9%−18.9%
September 22, 2021September 20, 2021 CRVS Sale $6,757,732 −68.2%−73.8%−77.0%
February 19, 2021February 17, 2021 CRVS Purchase $4,499,999 not yetnot yetnot yet
August 8, 2019August 6, 2019 CRVS Purchase $500,723 not yetnot yetnot yet
July 1, 2019June 27, 2019 CRVS Purchase $2,444,065 −44.4%−54.1%not yet
March 14, 2018March 12, 2018 CRVS Purchase $4,999,998 +27.8%−62.2%−59.7%
June 27, 2016June 23, 2016 CRVS Purchase $12,983 +11.4%−31.6%−33.7%
June 21, 2016June 17, 2016 CRVS Purchase $489,192 +7.5%−36.5%−30.5%
June 16, 2016June 14, 2016 CRVS Purchase $247,000 +18.3%−30.5%−29.3%
June 13, 2016June 9, 2016 CRVS Purchase $648,100 +32.9%−29.3%−41.0%
May 24, 2016May 20, 2016 CRVS Purchase $61,732 −8.3%−39.6%−39.7%
May 20, 2016May 18, 2016 CRVS Purchase $80,035 −10.9%−41.4%−20.9%

Open-market purchases and sales of at least $10,000 in companies we cover, from SEC Form 4 filings; sales made under a pre-set Rule 10b5-1 plan are not shown. “Not yet” means the window has not finished or the share price was under $5 at entry. These are the shares’ moves after each trade: they say nothing about why Thompson Peter A. traded and do not suggest the use of non-public information. How every insider compares · the insider trading backtest.